Nucleotide metabolism encompasses the synthesis and degradation of purines and pyrimidines, which are essential components of nucleic acids, energy transfer molecules such as ATP and GTP, coenzymes including NAD+ and FAD, and signaling molecules such as cAMP.
Purine Biosynthesis
Purine synthesis is a complex pathway that builds the purine ring system step by step on a ribose-5-phosphate scaffold. The pathway begins with ribose-5-phosphate, which is activated to 5-phosphoribosyl-1-pyrophosphate by PRPP synthetase. Ten sequential reactions assemble the complete purine ring, consuming four molecules of ATP, two molecules of glutamine, and one molecule each of glycine, aspartate, and formate.
The first committed step is the transfer of an amino group from glutamine to PRPP, catalyzed by amidophosphoribosyltransferase. This enzyme is inhibited by the end products AMP and GMP through feedback regulation. The final product is inosine monophosphate, which serves as the precursor for both AMP and GMP. IMP is converted to AMP through the insertion of an amino group from aspartate, while GMP is formed by oxidation followed by amidation using glutamine.
Purine Salvage
Free purine bases can be recycled through salvage pathways, which are energetically more efficient than de novo synthesis. Hypoxanthine-guanine phosphoribosyltransferase converts hypoxanthine and guanine to their corresponding nucleotides using PRPP. Adenine phosphoribosyltransferase salvages adenine. Deficiencies in these enzymes cause disease. HGPRT deficiency causes Lesch-Nyhan syndrome, characterized by uric acid overproduction, neurological dysfunction, and self-injurious behavior.
Purine Degradation
Purine nucleotides are broken down to uric acid. AMP is deaminated to IMP, then dephosphorylated to inosine, which is cleaved to hypoxanthine. Guanine is deaminated to xanthine. Xanthine oxidase converts hypoxanthine to xanthine and xanthine to uric acid, producing hydrogen peroxide as a byproduct. Uric acid is the final excretion product in humans and is eliminated in urine.
Pyrimidine Biosynthesis
Unlike purines, the pyrimidine ring is synthesized first and then attached to ribose-5-phosphate. The pathway begins with carbamoyl phosphate and aspartate. Carbamoyl phosphate synthetase II catalyzes the committed step, forming carbamoyl phosphate from glutamine, bicarbonate, and ATP. Aspartate transcarbamoylase then condenses carbamoyl phosphate with aspartate to form carbamoylaspartate. Dihydroorotase cyclizes the molecule, and dihydroorotate dehydrogenase, located on the outer mitochondrial membrane, introduces a double bond to form orotate. Orotate is then attached to PRPP by orotate phosphoribosyltransferase, and orotidine-5-phosphate is decarboxylated to form UMP.
Pyrimidine Salvage and Degradation
Pyrimidine salvage is less efficient than purine salvage. Uridine and cytidine can be phosphorylated by nucleoside kinases to form UMP and CMP. Pyrimidine degradation produces soluble products. Cytosine is deaminated to uracil, which is reduced to dihydrouracil and eventually broken down to beta-alanine, ammonia, and carbon dioxide. Thymine is degraded to beta-aminoisobutyrate.
Regulation of Nucleotide Metabolism
Like many metabolic pathways, the synthesis of purines and pyrimidines is tightly regulated to maintain balanced nucleotide pools. PRPP synthetase and amidophosphoribosyltransferase are inhibited by AMP and GMP. In pyrimidine synthesis, carbamoyl phosphate synthetase II is activated by PRPP and inhibited by UTP. Aspartate transcarbamoylase in bacteria shows classic allosteric regulation, with ATP as an activator and CTP as an inhibitor. The balance between purine and pyrimidine pools is coordinated through shared intermediates, with PRPP availability influencing both pathways.
Clinical Relevance
Disorders of nucleotide metabolism have significant clinical consequences. Gout results from uric acid accumulation and deposition in joints, treated by inhibiting xanthine oxidase with allopurinol. Severe combined immunodeficiency can result from adenosine deaminase deficiency, causing accumulation of toxic purine metabolites that kill developing lymphocytes. Anticancer and antiviral drugs often target nucleotide metabolism. Methotrexate inhibits dihydrofolate reductase, blocking nucleotide synthesis. 5-Fluorouracil inhibits thymidylate synthase, and 6-mercaptopurine is a purine analog incorporated into DNA.
